Barclays reiterated coverage on Amneal Pharmaceuticals with a new price target

3/1/21 7:31:15 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Barclays reiterated coverage of Amneal Pharmaceuticals with a rating of Overweight and set a new price target of $8.00 from $6.00 previously

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$AMRX

Date	Price Target	Rating	Analyst
6/6/2025	$12.00	Buy	Goldman
2/24/2025	$9.00 → $12.00	Neutral → Overweight	Analyst
9/6/2024	$9.00	Underweight → Neutral	JP Morgan